Multifunctional nanoparticles (NPs), composed of organic and inorganic materials, have
been explored as promising drug-delivery vehicles for cancer diagnosis and therapy. The …

Antibodies have been indispensable tools in molecular biology, biochemistry and medical
research. However, a number of issues surrounding validation, specificity and batch …

Purpose: Radiopharmaceutical therapy is changing the standard of care in prostate cancer
and other malignancies. We previously reported high CD46 expression in prostate cancer …

Multiple myeloma is incurable by standard approaches because of inevitable relapse and
development of treatment resistance in all patients. In our prior work, we identified a panel of …

We recently identified CD46 as a novel prostate cancer cell surface antigen that shows
lineage independent expression in both adenocarcinoma and small cell neuroendocrine …

Purpose: We recently identified CD46 as a novel therapeutic target in prostate cancer. In this
study, we developed a CD46-targeted PET radiopharmaceutical,[89Zr] DFO-YS5, and …

Effective treatments for de novo and treatment-emergent small-cell/neuroendocrine (t-
SCNC) prostate cancer represent an unmet need for this disease. Using metastatic biopsies …

Although initially responsive to androgen signaling inhibitors (ASIs), metastatic castration-
resistant prostate cancer (mCRPC) inevitably develops and is incurable. In addition to …

Background To date, the majority of protein-based radiopharmaceuticals have been
radiolabelled using non-site-specific conjugation methods, with little or no control to ensure …

Cancer is one of the major causes of death, annually claiming more than half a million lives
and there are an estimated 1.5 million new cases diagnosed in the USA [1]. Thus, there is an …